Navigation Links
KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission
Date:6/25/2008

Company Files Fiscal Form 10-Q's for First Three Quarters of Fiscal 2008

and Form 10-K for Fiscal 2008 Ended March 31, 2008

Points to Positive Fiscal 2009 Outlook for Its Branded and Generic

Pharmaceutical Businesses

ST. LOUIS, June 25 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology distinguished branded and generic/non-branded prescription pharmaceutical products, today announced that it has filed Form 10-Q's for the quarters ended June 30, 2007, September 30, 2007 and December 31, 2007, as well as a Form 10-K for its 2008 fiscal year ended March 31, 2008. The financial data included in these filings is consistent with previously reported preliminary financial results.

Marc S. Hermelin, Chairman of the Board and Chief Executive Officer stated, "With the filing of our fiscal 2008 financial reports, the Company is now up to date with its Securities and Exchange Commission filings. Fiscal 2008 was an extraordinary year for KV filled with many accomplishments by both our branded and generic businesses. Our Company continued to perform at record levels despite a difficult industry environment. We fully expect to continue our strong performance in fiscal 2009 and beyond as we execute on our branded and generic strategies and seek to capitalize on our valuable product pipeline."

Mr. Hermelin continued, "As previously reported, KV generated net revenue and net income increases of 36% and 52%, respectively, for fiscal 2008 compared to the prior year. In fiscal 2009 the Company expects to introduce 8-10 new products from Ther-Rx and ETHEX combined, which includes the anticipated approval of six ANDA's and one NDA. The anticipated new products, continued momentum from KV's generic Metoprolol Succinate Extended Release tablets, and expansion of the Company's branded women
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a ... announced its only mission and research focus: Water Life Science®. In the current ... water evaporation is becoming dangerously accelerated. As a result of the global fresh ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Having access to ... has led to an increasing amount of unnecessary emergency room visits which affects hospitals’ ... taxes the country’s health bill. Fortunately, a solution to alleviate this problem has recently ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... Residence in South Glastonbury, Connecticut, has been selected for the Residential Award of ... energy efficiency and resiliency measures. Chosen from a highly competitive field of submissions, ...
(Date:9/4/2015)... Charlotte, NC (PRWEB) , ... September 04, 2015 ... ... water filtration products, has a Labor Day offer that cannot be passed up. ... to stock up on necessary air and water filtration product replacements. Take advantage ...
(Date:9/3/2015)... , ... September 04, 2015 , ... AlignLife of ... September. , "There are so many children and adults who don't have the ... Dr. Sara Mahalko-Leonhardt. "We love holding our annual Coat Drive to help those in ...
Breaking Medicine News(10 mins):Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2
... motor disease, , WEDNESDAY, March 10 (HealthDay News) -- ... smoke and Parkinson,s disease, researchers have found that smoking ... but smoking a large number of cigarettes a day ... had suggested that smokers have a lower risk of ...
... technological revolution, the "light fantastic" continues to impact people,s ... and performing intricate surgery. As the golden anniversary of ... 7th, Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, ... exciting future of this amazing invention. C&EN ...
... ... HBS Alumnus Recognized for PrescriptionDrugs.com Business Plan , ... Boston, MA (PRWEB) March 11, 2010 -- A week ... their first ever HBS Alumni New Venture Contest . PrescriptionDrugs.com co-founder Mike “Zappy” ...
... A clinical research trial of a new treatment to ... safety stage, according to the UC Irvine neurologist who led ... no ill effects after the sequential administration of growth factors ... brain. All new drug treatments must pass this safety stage ...
... ... ... ... ...
... ... ... ... ...
Cached Medicine News:Health News:Longtime Smokers May Find Protection From Parkinson's 2Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 2Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 3Health News:New Consumer Era Places Retailers at the Forefront of Participating in Shoppers' Health 2Health News:New Consumer Era Places Retailers at the Forefront of Participating in Shoppers' Health 3Health News:New Consumer Era Places Retailers at the Forefront of Participating in Shoppers' Health 4Health News:Visionworks(R) Provides Eye Care For Pittsburgh's Smiling Irish Eyes 2Health News:Visionworks(R) Provides Eye Care For Pittsburgh's Smiling Irish Eyes 3
(Date:9/3/2015)... 3, 2015 Report Details What ... areas are going to grow at the fastest rates? ... 2025, assessing data, trends, opportunities and prospects there. ... graphs. Discover the most lucrative areas in the industry ... you assess forecasted sales at overall world market and ...
(Date:9/3/2015)... , Sept. 3,  2015 About ... bio-artificial devices, which are implanted or integrated ... organs. These include artificial heart, kidney, pancreas, ... polymers (polyurethane, polysulfone, and porous polypropylene), biologics, ... artificial organs. These organs are incorporated with ...
(Date:9/3/2015)... , Sept. 3, 2015  WellCare Health Plans, Inc. ... Asher , senior vice president and chief financial officer, ... 2015 Healthcare Conference on Wednesday, September 9, 2015, at ... be webcast live. In addition, a replay of the ... live broadcast. Both the live broadcast and the replay ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Global Artificial Organ Market 2015-2019 2
... International, Inc. (OTCQX: DATA), a technology and services company ... industry, today announced that it has been awarded its ... (CRO) in India, with which the Company had partnered ... to execute a Phase II study for the Dermatology ...
... Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... development, manufacturing, and marketing of branded and proprietary pharmaceuticals ... fourth quarter and fiscal year ended December 31, 2010. ... was RMB587.7 million (US$89.1 million) for the fourth quarter of ...
Cached Medicine Technology:DATATRAK Awarded First Study With Kreara Solutions 2DATATRAK Awarded First Study With Kreara Solutions 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 12